211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: Evaluation of relative biologic effectiveness of an α-emitter in vivo Journal Article


Authors: Bäck, T.; Andersson, H.; Divgi, C. R.; Hultborn, R.; Jensen, H.; Lindegren, S.; Palm, S.; Jacobsson, L.
Article Title: 211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: Evaluation of relative biologic effectiveness of an α-emitter in vivo
Abstract: The use of α-particle emitters in radioimmunotherapy (RIT) appears to be promising. We previously obtained convincing results in the treatment of microscopic intraperitoneal ovarian cancer in nude mice by using the α-emitter 211At. This study was performed to evaluate the relative biological effectiveness (RBE) of 211At compared with that of 60Co γ-irradiation in an RIT model. Our endpoint was growth inhibition (GI) of subcutaneous xenografts. Methods: GI after irradiation was studied with subcutaneous xenografts of the human ovarian cancer cell line NIH: OVCAR-3 implanted in nude mice. The animals received an intravenous injection of 211At-labeled monoclonal antibody MX35 F(ab′)2 at different levels of radioactivity (0.33, 0.65, and 0.90 MBq). Control mice received unlabeled MX35 F(ab′)2 only. To calculate the mean absorbed dose to tumor, a separate biodistribution study established the uptake of 211At in tumors and organs at different times after injection. External irradiation of the tumors was performed with 60Co. Tumor growth was monitored, and the normalized tumor volume (NTV) was calculated for each tumor. GI was defined by dividing the NTV values by the fitted NTV curve obtained from the corresponding control mice. To compare the biologic effects of the 2 radiation qualities, the mean value for GI (from day 8 to day 23) was plotted for each tumor as a function of its corresponding absorbed dose. From exponential fits of these curves, the doses required for a GI of 0.37 (D 37) were derived, and the RBE of 211At was calculated. Results: The biodistribution study showed the uptake of the immunoconjugate by the tumor (amount of injected radioactivity per gram) to be 14% after 7 h. At 40 h, the ratio of uptake in tumors to uptake in blood reached a maximum value of 6.2. The administered activities of 211At corresponded to doses absorbed by tumors of 1.35, 2.65, and 3.70 Gy. The value (mean ± SEM) for D37 was 1.59 ± 0.08 Gy. Tumor growth after 60Co external irradiation showed a value for D37 of 7.65 ± 1.0 Gy. The corresponding RBE of 211At irradiation was 4.8 ± 0.7. Conclusion: Using a tumor GI model in nude mice, we were able to derive an RBE of α-particle RIT with 211At. The RBE was found to be 4.8 ± 0.7.
Keywords: controlled study; unclassified drug; human cell; nonhuman; methodology; ovarian neoplasms; isotopes; mouse; animal; animals; mice; ovary cancer; in vivo study; tumor xenograft; cell line, tumor; mice, inbred balb c; radiation response; time; time factors; dose-response relationship, radiation; monoclonal antibody; antibodies, monoclonal; chemistry; bagg albino mouse; drug distribution; nude mouse; mice, nude; ovary tumor; tumor cell line; gamma irradiation; radiometry; relative biological effectiveness; radioisotope; neoplasm transplantation; cobalt; cobalt radioisotopes; drug half life; tumor growth; radioimmunotherapy; relative biologic effectiveness; radioisotopes; cobalt 60; isotope; cancer transplantation; xenografts; alpha radiation; alpha particles; astatine 211; monoclonal antibody mx35; astatine
Journal Title: Journal of Nuclear Medicine
Volume: 46
Issue: 12
ISSN: 0161-5505
Publisher: Society of Nuclear Medicine  
Date Published: 2005-12-01
Start Page: 2061
End Page: 2067
Language: English
PUBMED: 16330571
PROVIDER: scopus
DOI/URL:
Notes: --- - "Cited By (since 1996): 25" - "Export Date: 24 October 2012" - "CODEN: JNMEA" - "Source: Scopus"
Citation Impact
MSK Authors
  1. Chaitanya Divgi
    163 Divgi